16 / 43
ORR, PFS, AND OS: INTENTION TO TREAT
a
23% of patients in the NIVO + IPI arm and 25% of patients in
the SUN arm had tumor PD-L1 expression ≥1%
b
IRRC-assessed by RECIST v1.1
c
IRRC-assessed
N = 1,096
a
Outcome
NIVO + IPI
N = 550
SUN
N = 546
ConfirmedORR,
b
% (95%
CI)
39 (35–43)
32 (28–36)
P
= 0.0191
PFS,
c
median (95% CI),
months
12.4 (9.9–
16.5)
12.3 (9.8–
15.2)
HR (99.1% CI) 0.98 (0.79–
1.23)
P
= 0.8498
550 523 492 464 443 426 404 339 197 71 4 0
546 506 471 432 402 363 334 283 173 66 6 0
Overall Survival (Probability)
0.8
0.9
1.0
0.4
0.5
0.6
0.7
0
6
12
18
24
0.1
0.0
0.2
0.3
33 30
3
9
15
21
27
Months
No. at Risk
NIVO + IPI
HR (99.8% CI) 0.68 (0.49–0.95)
P
= 0.0003
Median OS, months (95% CI)
NIVO + IPI
NR (NE–NE)
SUN
32.9 (NE–NE)
Secondary endpoint
Escudier B, et al. ESMO 2017; LBA5